Hydra Biosciences Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $22.6M

  • Investors
  • 1

Hydra Biosciences General Information

Description

Developer of molecular regeneration medicines intended to treat pain, inflammation, anxiety, and other diseases. The company's medicines focuses in the field of Transient Receptor Potential (TRP) ion channels, enabling doctors to address significant unmet medical needs easily.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 45 Moulton Street
  • Cambridge, MA 02138
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 45 Moulton Street
  • Cambridge, MA 02138
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hydra Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 01-Dec-2018 $22.6M Completed Generating Revenue
8. Later Stage VC (Series E) 31-Mar-2015 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series D) 16-Jan-2009 Completed Generating Revenue
6. Later Stage VC (Series C) 13-Mar-2008 Completed Generating Revenue
5. Early Stage VC (Series B) 12-Jan-2004 Completed Startup
4. Accelerator/Incubator 01-Jan-2003 Completed Startup
3. Early Stage VC 09-Oct-2002 Completed Startup
2. Early Stage VC (Series A) 25-Jul-2002 $9.3M $9.3M Completed Startup
1. University Spin-Out 01-Jan-2001 Completed Startup
To view Hydra Biosciences’s complete valuation and funding history, request access »

Hydra Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D
Series C
Series B1
Series B
Series A1 1,065,004 $0.001000 8% $10 $10 1x $10
Series A 1,065,004 $0.001000 8% $10 $10 1x $5.55 1.86%
To view Hydra Biosciences’s complete cap table history, request access »

Hydra Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of molecular regeneration medicines intended to treat pain, inflammation, anxiety, and other diseases. The com
Drug Discovery
Cambridge, MA

Basel, Switzerland

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hydra Biosciences Competitors (83)

One of Hydra Biosciences’s 83 competitors is Baliopharm, a Venture Capital-Backed company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Baliopharm Venture Capital-Backed Basel, Switzerland
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
Orchard Therapeutics Formerly VC-backed London, United Kingdom
MicroCures Venture Capital-Backed Santa Cruz, CA
Pharmacyclics Venture Capital-Backed San Francisco, CA
You’re viewing 5 of 83 competitors. Get the full list »

Hydra Biosciences Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abbott Corporation Minority
Abbott Ventures Corporate Venture Capital Minority
Abingworth Venture Capital Minority
Acceleration International Growth/Expansion Minority
Advanced Technology Ventures Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Hydra Biosciences FAQs

  • When was Hydra Biosciences founded?

    Hydra Biosciences was founded in 2001.

  • Where is Hydra Biosciences headquartered?

    Hydra Biosciences is headquartered in Cambridge, MA.

  • What industry is Hydra Biosciences in?

    Hydra Biosciences’s primary industry is Drug Discovery.

  • Is Hydra Biosciences a private or public company?

    Hydra Biosciences is a Private company.

  • What is the current valuation of Hydra Biosciences?

    The current valuation of Hydra Biosciences is .

  • What is Hydra Biosciences’s current revenue?

    The current revenue for Hydra Biosciences is .

  • How much funding has Hydra Biosciences raised over time?

    Hydra Biosciences has raised $95.7M.

  • Who are Hydra Biosciences’s investors?

    Abbott, Abbott Ventures, Abingworth, Acceleration International, and Advanced Technology Ventures are 5 of 14 investors who have invested in Hydra Biosciences.

  • Who are Hydra Biosciences’s competitors?

    Baliopharm, Neurona Therapeutics, Orchard Therapeutics, MicroCures, and Pharmacyclics are some of the 83 competitors of Hydra Biosciences.

  • When was Hydra Biosciences acquired?

    Hydra Biosciences was acquired on 01-Dec-2018.

  • Who acquired Hydra Biosciences?

    Hydra Biosciences was acquired by Lilly USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process